A design, recruitment, and baseline-characteristics report for the PREDIABETEXT cluster randomised trial of a digital diabetes-prevention intervention, with no efficacy outcomes yet reported. PICO summary and expert commentary.
Browsing: Diabetes Technology & Monitoring
Continuous glucose monitoring, insulin pumps, closed-loop systems, and digital tools in diabetes care.
A 2-centre factorial RCT in 273 Chinese adults with type 2 diabetes found the Dnurse app did not significantly improve HbA1c attainment, though systolic blood pressure fell in the app arms. PICO summary and expert commentary.
A manufacturer-funded cost-effectiveness model found the MiniMed 780G closed-loop system cost-effective versus injections with isCGM in US type 1 diabetes at $100,000 per QALY (ICER $68,402 over 4 years, $38,842 lifetime). PICO summary and expert commentary.
A small open-label Spanish RCT found a digital education program added to GLP-1 therapy produced greater HbA1c, weight, and adherence gains than usual care over six months. PICO summary and expert commentary.
A three-arm randomized trial in Texans with uncontrolled type 2 diabetes found that all three self-paced virtual and technology-based self-management programs significantly reduced A1c, with no in-person comparator. PICO summary and expert commentary.
A single-arm extension found HbA1c was sustained over 30 weeks in adults with type 1 diabetes who switched to inhaled technosphere insulin plus degludec. PICO summary and expert commentary.
A 13-week single-arm switch study tested inhaled technosphere insulin plus degludec against participants’ own baseline in 49 adults with type 1 diabetes. PICO summary and expert commentary.
A single-centre randomized trial testing an integrated data platform plus dietary management against routine care in 180 adults with type 2 diabetes. PICO summary and expert commentary.
A single-centre RCT (n=180) testing an integrated cloud data platform with dietary management and education videos against routine care in type 2 diabetes, with HbA1c lower at 12 weeks. PICO summary and expert commentary.
A single-center randomized controlled trial testing a cloud-hospital data platform plus dietary management against standard care in 180 adults with type 2 diabetes, reporting a modest 12-week HbA1c advantage. PICO summary and expert commentary.